Michael Marchetti, DO
Sports Medicine · Norwalk, CTNPI 1316384613
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Polaris Technology Solutions LLC at 27.1% of the total. 2025 is the largest year on record at $250, more than ten times the $11 reported in 2020. That places this record below the midpoint for sports medicine clinicians in CT, where the typical reported total is $1,485.
Across 16 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Polaris Technology Solutions LLC$136
- Johnson & Johnson$83
- Stryker$65
- AbbVie$44
- Bioventus LLC$25
- Amarin Pharma, Inc.$25
- plus $126 from 8 others
What the payments were for
- Food & beverage$504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Polaris Technology Solutions LLC | 1 | $136 |
| Johnson & Johnson | 1 | $83 |
| Stryker | 2 | $65 |
| AbbVie | 2 | $44 |
| Bioventus LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Cerapedics Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Pfizer | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Amgen | 1 | $11 |
How this compares
$504 in reported general payments places this provider in the 35th percentile of 65 sports medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $55,782 |
| EliquisApixaban | 17 | $24,425 |
| JardianceEmpagliflozin | 12 | $21,177 |
| MounjaroTirzepatide | 19 | $19,599 |
| JanuviaSitagliptin Phosphate | 11 | $16,509 |
| FarxigaDapagliflozin Propanediol | 12 | $14,206 |
| SynthroidLevothyroxine Sodium | 39 | $3,678 |
| Atorvastatin Calcium | 297 | $2,395 |
| Levothyroxine Sodium | 147 | $1,664 |
| Lisinopril | 229 | $1,506 |
| Rosuvastatin Calcium | 116 | $1,498 |
| Escitalopram Oxalate | 64 | $1,251 |
| Amlodipine Besylate | 171 | $1,198 |
| Gabapentin | 51 | $1,191 |
| Metoprolol Succinate | 75 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $24,42517 claims |
| Lilly USA, LLCMounjaro | $18 | $19,59919 claims |
| AstraZenecaFarxiga | $15 | $14,20612 claims |
| AbbVieSynthroid | $44 | $3,67839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 65 sports medicine providers in Connecticut.
Other sports medicine in Norwalk
- Joshua FrankNorwalk$78K
- Augustus MazzoccaFarmington$1M
- Michael KaplanMiddlebury$385K
- Robert ArcieroFarmington$269K
- Karen SuttonStamford$245K
- Michael KuhnMiddletown$201K
- Katherine CoynerFarmington$186K
- Michael JoyceGlastonbury$73K
- Andrew JimenezNew Haven$66K
- Jordan GruskayBranford$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.